FDA Inspection 1162502 — Bloodworks
The FDA completed an inspection of Bloodworks on Feb 9, 2022 in Bellingham, WA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Feb 9, 2022
- Fiscal Year
- 2022
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Bellingham, WA (United States)